Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2016—Chembio Diagnostics will begin selling its Sure Check HIV 1/2 Assay in the U.S. market on June 1. The product is currently distributed in the United States by Alere under Alere’s Clearview Complete brand, and Chembio has notified Alere that it will not renew or extend the distribution agreement when it terminates on May 31.
March 2016—SciGene introduced a high-capacity system for performing FISH hybridization assays. The system consists of one CytoBrite Slide Incubation System for performing rapid probe denaturation on batches of 12 FISH slides and one CytoBrite Slide Oven for overnight hybridizations of 60 slides. Removable slide trays streamline slide setup and transfers between instruments.
March 2016—Sakura Finetek USA announced the acquisition of Genemed Biotechnologies’ tissue-based advanced staining business for cancer detection, diagnosis, and monitoring. Genemed’s liquid-based molecular testing products were not included in the acquisition and will be spun out as an independent business.
March 2016—ScyTek Laboratories announced the availability of its Multiplex TTF-1 and Cytokeratin 5 Cocktail. This multiplex cocktail of TTF-1 and cytokeratin 5 produces two-color, high-contrast staining for differentiating primary adenocarcinoma of the lung from metastatic carcinomas of the breast and malignant mesothelioma. This cocktail can increase sensitivity and diagnostic utility in differential diagnosis of the tumor.
March 2016—PerkinElmer has acquired Vanadis Diagnostics. Based in Sweden, Vanadis is developing a novel solution for non-invasive prenatal testing based on digital analysis of cell-free DNA.
March 2016—Definiens released its Tissue Studio 4.2 software package. The updated product suites provide improved image analysis functionality for scientists in academic medical centers, comprehensive cancer centers, and biotech and pharmaceutical companies.
March 2016—Quidel has received the CE mark for its Sofia S. pneumoniae fluorescent immunoassay for use with the Sofia Fluorescent Immunoassay Analyzer. The Sofia S. pneumoniae FIA enables the qualitative detection of Streptococcus pneumoniae antigen in the urine of patients with pneumonia and in the cerebral spinal fluid of patients with meningitis in 10 minutes.
March 2016—Medivation and NanoString Technologies have entered into a collaboration, together with Astellas Pharma, to pursue the translation of a novel gene expression signature algorithm from Medivation into a companion diagnostic assay using NanoString’s nCounter Dx Analysis System.
March 2016—Quantimetrix introduced a new formulation for Dip&Spin Urinalysis Dipstick/Microscopics Control. The formulation now features improved crystal sediment components with calcium oxalate dihydrate in their native octahedral morphology and are readily identifiable via standard light microscopy and automated microscopy methods.
March 2016—Advanced Biological Laboratories launched its DeepChek SingleRound HIV and Hepatitis C Virus Genotyping and Sequencing assays. The DeepChek SingleRound HIV RT-PCR and Sequencing Assay detects the major HIV-1 subtypes and combines the reagents (including enzymes) and protocols required to perform the amplification and sequencing of reverse transcriptase, protease, and integrase.
